Creative Biolabs Competent in Providing Professional iPSC Differentiation Services

August 23 19:26 2022
With advanced technology and excellent iPSC scientists, Creative Biolabs is committed to providing customers with first-class iPSC differentiation services.

New York, USA – August 23, 2022 – As a revolutionary technology, iPSC opens up a whole new path for the development of regenerative medicine. iPSCs exhibit the unique ability to differentiate into any cell type if provided with the correct stimulations. This technology enables the generation of disease-relevant tissues from patients in scalable quantities. Both iPSC-derived organs and organoids are currently evaluated for regenerative therapy, further contributing toward clinical trials and disease modeling, as well as facilitating drug screening efforts for the discovery of novel therapeutics.

Creative Biolabs operates an advanced platform and is capable of providing stem cell differentiation services for its clients. Scientists at Creative Biolabs can generate iPSCs from patient material, thus, generating various cell types.

iPSC differentiation services at Creative Biolabs include but are not limited to:

Hepatocytes Differentiation from iPSC

• Cardiomyocytes Differentiation from iPSC

• Neuronal Cells Differentiation from iPSC

iPSC-derived hepatocytes provide a stable, readily available cell source for application, which previously required human primary hepatocyte or hepatoma cell lines. The generation of iPSC-derived hepatocytes serves as a potential source for therapeutic applications and further enables in vitro study of liver diseases.

Creative Biolabs provides hepatocyte differentiation services, ranging from iPSC to generating iPSC-derived hepatocytes used for disease modeling, drug screening, metabolism, as well as toxicological studies.

Creative Biolabs can control three important sequential processes in the generation of hepatocytes, which further differentiate into defined endoderm, liver progenitor cells, and mature hepatocytes.

In addition to liver disease, iPSC also demonstrates promising application in cardiovascular diseases (CVDs). Over recent decades, CVDs have become the leading cause of death globally, taking an estimated 17.9 million lives each year. Cardiovascular regenerative medicine is a new approach that promises exciting transformations in the current medical field. This would prove substantial toward the care of millions of people worldwide, among which human-induced pluripotent stem cells (hiPSCs) prove most promising as a cell type. Currently, scientists at Creative Biolabs have developed three major approaches to generating iPSC-derived cardiomyocytes: Embryoid (EB), monolayer culture, and inductive coculture.

The differentiation of EBs remains, first and foremost, the most common method to obtain cardiomyocytes. An alternative approach for the differentiation of hiPSCs is based on the monolayer. Compared to EBs, the monolayer protocol has fewer procedural steps as well as is easier to control and reproduce growth factor regulation and other interventions. Induced coculture is also a differentiation strategy in which iPSCs are co-cultured with a visceral endoderm-like cell line (END-2).

Find out more information about Creative Biolabs’ iPSC services at

About Creative Biolabs

Creative Biolabs operates from a well-developed platform equipped with advanced technologies to provide comprehensive solutions for iPSC projects, including generation, bioprocess scale-up, and differentiation of iPSCs.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States